[PD-1抑制剂联合来那度胺治疗复发性CD5+弥漫大B细胞淋巴瘤的临床分析】。]

Q4 Medicine
Ya-Ping Wang, Xue-Ya Zhang
{"title":"[PD-1抑制剂联合来那度胺治疗复发性CD5+弥漫大B细胞淋巴瘤的临床分析】。]","authors":"Ya-Ping Wang, Xue-Ya Zhang","doi":"10.19746/j.cnki.issn.1009-2137.2024.04.021","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To investigate the clinical characteristics and treatment of relapsed CD5<sup>+</sup> diffuse large B-cell lymphoma (DLBCL).</p><p><strong>Methods: </strong>The data of a patient with CD5<sup>+</sup> DLBCL was collected, and its clinical characteristics and treatment outcome were analyzed.</p><p><strong>Results: </strong>The patient developed hemophagocytic syndrome and achieved complete remission (CR) after 6 cycles of R-ECHOP chemotherapy, then relapsed. After 2 cycles of PD-1 inhibitor combined with lenalidomide treatment, the patient achieved CR again accompanied by a decrease of interleukin (IL)-10 expression level. After a total of 15 cycles of chemotherapy, the patient remained in CR for 24 months, and the level of IL-10 remained in the normal range.</p><p><strong>Conclusion: </strong>PD-1 inhibitor combined with lenalidomide regimen may be a new treatment for relapsed CD5<sup>+</sup> DLBCL.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"32 4","pages":"1112-1116"},"PeriodicalIF":0.0000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Clinical Analysis of PD-1 Inhibitor Combined with Lenalidomide in Treatment of Relapsed CD5<sup>+</sup> Diffuse Large B-Cell Lymphoma].\",\"authors\":\"Ya-Ping Wang, Xue-Ya Zhang\",\"doi\":\"10.19746/j.cnki.issn.1009-2137.2024.04.021\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To investigate the clinical characteristics and treatment of relapsed CD5<sup>+</sup> diffuse large B-cell lymphoma (DLBCL).</p><p><strong>Methods: </strong>The data of a patient with CD5<sup>+</sup> DLBCL was collected, and its clinical characteristics and treatment outcome were analyzed.</p><p><strong>Results: </strong>The patient developed hemophagocytic syndrome and achieved complete remission (CR) after 6 cycles of R-ECHOP chemotherapy, then relapsed. After 2 cycles of PD-1 inhibitor combined with lenalidomide treatment, the patient achieved CR again accompanied by a decrease of interleukin (IL)-10 expression level. After a total of 15 cycles of chemotherapy, the patient remained in CR for 24 months, and the level of IL-10 remained in the normal range.</p><p><strong>Conclusion: </strong>PD-1 inhibitor combined with lenalidomide regimen may be a new treatment for relapsed CD5<sup>+</sup> DLBCL.</p>\",\"PeriodicalId\":35777,\"journal\":{\"name\":\"中国实验血液学杂志\",\"volume\":\"32 4\",\"pages\":\"1112-1116\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中国实验血液学杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.19746/j.cnki.issn.1009-2137.2024.04.021\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国实验血液学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2024.04.021","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

目的研究复发的CD5+弥漫大B细胞淋巴瘤(DLBCL)的临床特征和治疗方法:收集一名CD5+ DLBCL患者的资料,分析其临床特征和治疗结果:患者出现嗜血细胞综合征,在接受6个周期的R-ECHOP化疗后获得完全缓解(CR),随后复发。PD-1抑制剂联合来那度胺治疗2个周期后,患者再次获得CR,同时白细胞介素(IL)-10表达水平下降。经过总共15个周期的化疗后,患者的CR维持了24个月,IL-10的水平也保持在正常范围:结论:PD-1抑制剂联合来那度胺方案可能是复发CD5+ DLBCL的一种新疗法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
[Clinical Analysis of PD-1 Inhibitor Combined with Lenalidomide in Treatment of Relapsed CD5+ Diffuse Large B-Cell Lymphoma].

Objective: To investigate the clinical characteristics and treatment of relapsed CD5+ diffuse large B-cell lymphoma (DLBCL).

Methods: The data of a patient with CD5+ DLBCL was collected, and its clinical characteristics and treatment outcome were analyzed.

Results: The patient developed hemophagocytic syndrome and achieved complete remission (CR) after 6 cycles of R-ECHOP chemotherapy, then relapsed. After 2 cycles of PD-1 inhibitor combined with lenalidomide treatment, the patient achieved CR again accompanied by a decrease of interleukin (IL)-10 expression level. After a total of 15 cycles of chemotherapy, the patient remained in CR for 24 months, and the level of IL-10 remained in the normal range.

Conclusion: PD-1 inhibitor combined with lenalidomide regimen may be a new treatment for relapsed CD5+ DLBCL.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
中国实验血液学杂志
中国实验血液学杂志 Medicine-Medicine (all)
CiteScore
0.40
自引率
0.00%
发文量
7331
期刊介绍:
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信